Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis
暂无分享,去创建一个
[1] R. Bank,et al. The RAGE G82S polymorphism is not associated with rheumatoid arthritis independently of HLA-DRB1*0401. , 2006, Rheumatology.
[2] C. Tıkız,et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. , 2005, The Journal of rheumatology.
[3] P. Gregersen,et al. The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. , 2005, Atherosclerosis.
[4] A. Silman,et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. , 2005, Arthritis and rheumatism.
[5] Andrej Tarkowski,et al. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control , 2005, Arthritis research & therapy.
[6] N. Goodson,et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s , 2005, Annals of the rheumatic diseases.
[7] S. Gabriel,et al. Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.
[8] F. Ruschitzka,et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. , 2005, Journal of the American College of Cardiology.
[9] I. McInnes,et al. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? , 2005, Arthritis research & therapy.
[10] N. Wheeldon,et al. Active inflammatory bowel disease and coronary artery dissection , 2005, Postgraduate Medical Journal.
[11] G. McColl,et al. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[12] E. Rimm,et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[13] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[14] R. Madhok,et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.
[15] O Fitzgerald,et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. , 2003, Rheumatology.
[16] M. Andrassy,et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. , 2003, The Journal of clinical investigation.
[17] M. Yamakuchi,et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. , 2003, Arthritis and rheumatism.
[18] A. Silman,et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. , 2002, Arthritis and rheumatism.
[19] B. Joffe,et al. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis , 2002, Arthritis research.
[20] P. Gregersen,et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response , 2002, Genes and Immunity.
[21] N. de Vries,et al. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. , 2002, Arthritis and rheumatism.
[22] R. de Caterina,et al. Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.
[23] G L Freeman,et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.
[24] K. Thygesen,et al. Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .
[25] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[26] Hugo A. Katus,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.
[27] I. Fajardy,et al. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[28] C. Suh,et al. Lipid profiles in untreated patients with rheumatoid arthritis. , 1999, The Journal of rheumatology.
[29] A. Hofman,et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[30] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[31] P. Shekelle,et al. How to read radiographs according to the Sharp/van der Heijde method. , 1999 .
[32] P. Grant,et al. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. , 1998, Diabetes.
[33] R. D. Situnayake,et al. Dyslipidaemia and rheumatoid arthritis , 1997 .
[34] T. Ikemura,et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. , 1994, Genomics.
[35] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[36] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[37] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[38] P. Gregersen,et al. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.
[39] R. Siegel,et al. Cardiovascular manifestations of systemic lupus erythematosus. , 1985, American heart journal.
[40] I. Das,et al. Raised C-reactive protein levels in serum from smokers. , 1985, Clinica chimica acta; international journal of clinical chemistry.
[41] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[42] H. Makino,et al. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[43] Le-Xin Wang,et al. Rheumatoid arthritis increases the risk of coronary heart disease via vascular endothelial injuries. , 2004, Medical hypotheses.
[44] D. M. van der Heijde,et al. How to read radiographs according to the Sharp/van der Heijde method. , 1999, The Journal of rheumatology.
[45] R. D. Situnayake,et al. Dyslipidemia and rheumatoid arthritis. , 1997, Annals of the rheumatic diseases.
[46] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.